Evidence map›Paper›PMID 28076879›Full record

ArticleClinical and experimental immunology2017

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

J M Clain, A M Hummel, J H Stone, F C Fervenza, G S Hoffman, C G M Kallenberg, C A Langford, W J McCune, P A Merkel, P A Monach and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Analysis of Antineutrophil Cytoplasm Antibody from 118 730 Patients in Tertiary Hospitals in Jiangxi Province, China.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 2 countries.

J M ClainMayo Clinic and Foundation, Rochester, MN, USA.
A M HummelMayo Clinic and Foundation, Rochester, MN, USA.
J H StoneMassachusetts General Hospital, Boston, MA, USA.
F C FervenzaMayo Clinic and Foundation, Rochester, MN, USA.
G S HoffmanCleveland Clinic Foundation, Cleveland, OH, USA.
C G M KallenbergUniversity of Groningen, Groningen, the Netherlands.
C A LangfordCleveland Clinic Foundation, Cleveland, OH, USA.
W J McCuneUniversity of Michigan, Ann Arbor, MI, USA.
P A MerkelUniversity of Pennsylvania, Philadelphia, PA, USA.
P A MonachBoston University Medical Center, Boston, MA, USA.
P SeoJohns Hopkins University, Baltimore, MD, USA.
R F SpieraHospital for Special Surgery, New York, NY, USA.
E W St ClairDuke University, Durham, NC, USA.
S R YtterbergMayo Clinic and Foundation, Rochester, MN, USA.
U SpecksMayo Clinic and Foundation, Rochester, MN, USA.
WGET and RAVE-ITN Research Groups
Mayo Clinic · USCleveland Clinic · USBoston University · USDuke University · USHospital for Special Surgery · USJohns Hopkins University · USMassachusetts General Hospital · USUniversity of Groningen · NLUniversity of Michigan–Ann Arbor · USUniversity of Pennsylvania · US

Funding

Immune Tolerance Network: Type 1 diabetesN01AI15416 · NIAID · UNIVERSITY OF SAN FRANCISCO · PI BLUESTONE, JEFFREY · 2007 to 2013
$276.6M
Institute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8M
MAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4M
YOGA INDUCED CHANGES IN BRAIN GABA LEVELSM01RR000533 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HOLICK, MICHAEL F. · 1985 to 2008
$19.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025771 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CENTER, DAVID M. · 2008 to 2011
$17.6M
RANDOMIZED CLINICAL TRIAL OF ETANERCEPT IN WEGENER'S-264992240N01AR092240 · NIAMS · JOHNS HOPKINS UNIVERSITY · 1999 to 2003
$829k
Development of an ANCA-Vasculitis Index of Damage (AVID)K23AR052820 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI SEO, PHILIP · 2005 to 2009
$661k
Studies in Scleroderma and Cystic Fibrosis OsteoporosisK24AR002224 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MERKEL, PETER A · 2001 to 2005
$609k
Translational Research in Systemic VasculitisK24AR049185 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI STONE, JOHN H · 2003 to 2006
$351k
IMMUNE TOLERANCE NETWORK-266015416-266015416N01AI015416 · NIAID · REGENTS OF THE UNIVERSITY OF C · PI BLUESTONE, JEFFREY A · 2002 to 2006
–
NCRR NIH HHS M01 RR000533NCRR NIH HHS UL1 RR024150NCRR NIH HHS UL1 RR025005NCRR NIH HHS UL1 RR025771NIAID NIH HHS N01AI15416NIAMS NIH HHS K23 AR052820NIAMS NIH HHS K24 AR002224NIAMS NIH HHS K24 AR049185NIAMS NIH HHS N01 AR092240
6 · The paper itself

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) appear to play an important role in the pathogenesis of ANCA-associated vasculitis (AAV). However, ANCA alone are not sufficient to generate disease, and some evidence suggests that infectious triggers may serve as inciting events for AAV disease activity. Antibodies of the immunoglobulin (Ig)M isotype often serve as markers of recent infection, and IgM ANCA have been identified previously in patients with AAV, although the frequency and clinical relevance of IgM ANCA is not well established. We sought to characterize IgM ANCA more clearly by creating a novel enzyme-linked immunosorbent assay (ELISA) for IgM antibodies to proteinase 3 [IgM proteinase 3 (PR3)-ANCA], which we applied to two large, clinically well-characterized trial cohorts of patients with granulomatosis with polyangiitis and microscopic polyangiitis. In the first cohort, IgM PR3-ANCA occurred with a frequency of 15·0%, and were associated with a higher degree of disease severity and a trend towards a higher rate of alveolar haemorrhage (29·6 versus 15·7%, P = 0·10). Analysis of follow-up samples in this cohort showed that the presence of IgM PR3-ANCA was transient, but could recur. In the second cohort, IgM PR3-ANCA occurred with a frequency of 41·1%, and were also associated with a higher degree of disease severity. A higher rate of alveolar haemorrhage was observed among those with IgM PR3-ANCA (45·3 versus 15·8%; P < 0·001). The association of transient IgM PR3-ANCA with an acute respiratory manifestation of AAV suggests a possible link between an infectious trigger and AAV disease activity.

Indexed as

AdultAgedAntibodies, Antineutrophil CytoplasmicAutoantibodiesBiomarkersFemaleGranulomatosis with PolyangiitisHumansImmunoglobulin GImmunoglobulin MMaleMicroscopic PolyangiitisMiddle AgedMyeloblastinSeverity of Illness IndexAntibodies, Antineutrophil CytoplasmicAutoantibodiesBiomarkersImmunoglobulin GImmunoglobulin MMyeloblastinalveolar haemorrhageANCA-associated vasculitisanti-neutrophil cytoplasmic antibodiesgranulomatosis with polyangiitisimmunoglobulin Mmicroscopic polyangiitis

Identifiers

PMID28076879
PMCPMC5343341
OpenAlexW2578342810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.